Cardiovascular Safety and State-of-the-art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity

17 - 18 April 2012, Washington, DC, United States

Introduction

Join Industry Experts and Regulators to Improve Your Safety Analysis During Drug Development, Analyze and Mitigate Potential Risks, and Explore New Solutions and Approaches to Developing Safe and Effective Medications, including those to treat Type 2 Diabetes Mellitus.

Event Code:
12009

Useful links

Venue

Washington Marriott Hotel

Washington Marriott Hotel, Washington, DC, 20037, United States

Organised by

DIA

Contact information

Rachel Minnick
United States of America
2154426131
Contact us by email

91AV

Share:

Cardiovascular Safety and State-of-the-art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity

17 - 18 April 2012, Washington, DC, United States

Useful links

Search

Exclude Online events

Select date range

Start Date

End Date

Location

Subject area

Event type

91AV

Share:

Cardiovascular Safety and State-of-the-art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity

17 - 18 April 2012, Washington, DC, United States

Useful links

Related events

New Zealand Institute of 91AV Conference 2024 (NZIC-24)

24 November 2024 14:00 - 28 November 2024 14:00, Dunedin, New Zealand

Drugging the Multimorbidity Associated with Ageing

17 January 2025 09:30-17:00, London, United Kingdom

Future Labs Live Basel

27 May 2025 09:00 - 28 May 2025 17:00, Basel, Switzerland

European Glycoscience Community Webinar Series

25 January 2024 15:00 - 19 December 2024 18:00

Search

Exclude Online events

Select date range

Start Date

End Date

Location

Subject area

Event type